This research topic aims to provide an overview of the most recent advancements in understanding molecular mechanisms to develop biomarkers that can be selectively addressed to enhance the diagnosis, prognosis, and therapeutic interventions in gastrointestinal (GI) disorders and sepsis. Molecular biomarkers include peptides, lipids metabolites, nucleic acids (DNA and RNA), and others identified through metabolomics, lipidomics, glycomics, genomics, transcriptomics, proteomics, and secretomics methodologies. The identification of optimal biomarkers is of paramount importance as it holds significant potential for the advancement of personalized medicine and the overall improvement of clinical outcomes. GI disorders encompass a spectrum of pathological conditions affecting the gastrointestinal tract, encompassing various illnesses such as indigestion, inflammatory bowel diseases (IBDs), and malignant tumors. Intestinal barrier dysfunction leading to increased permeability facilitates the release of luminal contents, such as intact microbes and microbial products, which can cause severe sepsis and potentially fatal outcomes if prompt treatment is not administered.
Considering the global epidemiology of GI disorders and sepsis, biomarkers enable and improve their diagnosis, prognosis, and treatment. This research topic highlights the effectiveness and limitations of biomarkers used in GI disorders, such as gut barrier proteins and microbial fermentation byproducts, including short-chain fatty acids, calprotectin, several microRNAs (miRNAs) including miRNA-146a, fatty acid-binding protein, urinary metabolomics (tricarboxylic acid and amino acids). This research topic also covers the application of other potential noninvasive biomarkers for diagnosing and monitoring GI disorders. GI cancers are widely regarded as the most harmful and clinically severe conditions affecting the digestive system. In individuals who do not exhibit clinical signs, biomarkers can function as a valuable tool for screening to detect cancer at an early stage or identify precancerous states and, in symptomatic patients, can help distinguish between cancerous and benign conditions. Additionally, with surgical intervention in cancer patients, biomarkers can be useful to assess the efficacy of tumor eradication (remission) and the likelihood of disease relapse. This research topic addresses the latest developments in genetic biomarkers but is not limited to miRNAs and long non-coding RNAs, KRAS mutations, the role of carcinoembryonic antigen, and circulating tumor DNA (ctDNA) as molecular biomarkers for GI malignancies. This topic also explores recent advancements in sepsis biomarkers, including damage-associated molecular patterns (DAMPs), pattern recognition molecules (PRMs), non-coding RNAs, miRNAs, cytokines, cell membrane receptors, metabolites, and soluble receptors. It also discusses the therapeutic challenges posed by antimicrobial resistance and their impact on One Health.
All articles must include genomics or omics data as a central part of their methods. The Research Topic aims to focus on the latest advancements in the field, encompassing both basic research and clinical studies, and invites submissions of Original Research, Reviews, and Methods but is not confined to the following areas:
• Fecal biomarkers for diagnosing and monitoring gastrointestinal disorders
• Identification and characterization of biomarkers for colorectal cancer
• Non-invasive biomarkers for gastrointestinal illnesses
• MicroRNA (miRNA) biomarkers in GI diseases
• Sepsis Biomarkers
• Signaling pathways in sepsis and GI diseases
• Epigenetic biomarkers for GI cancer diagnosis and prognosis
• GI disease epigenetic mechanisms
• Epigenetic biomarkers for GI diseases and sepsis
This research topic aims to provide an overview of the most recent advancements in understanding molecular mechanisms to develop biomarkers that can be selectively addressed to enhance the diagnosis, prognosis, and therapeutic interventions in gastrointestinal (GI) disorders and sepsis. Molecular biomarkers include peptides, lipids metabolites, nucleic acids (DNA and RNA), and others identified through metabolomics, lipidomics, glycomics, genomics, transcriptomics, proteomics, and secretomics methodologies. The identification of optimal biomarkers is of paramount importance as it holds significant potential for the advancement of personalized medicine and the overall improvement of clinical outcomes. GI disorders encompass a spectrum of pathological conditions affecting the gastrointestinal tract, encompassing various illnesses such as indigestion, inflammatory bowel diseases (IBDs), and malignant tumors. Intestinal barrier dysfunction leading to increased permeability facilitates the release of luminal contents, such as intact microbes and microbial products, which can cause severe sepsis and potentially fatal outcomes if prompt treatment is not administered.
Considering the global epidemiology of GI disorders and sepsis, biomarkers enable and improve their diagnosis, prognosis, and treatment. This research topic highlights the effectiveness and limitations of biomarkers used in GI disorders, such as gut barrier proteins and microbial fermentation byproducts, including short-chain fatty acids, calprotectin, several microRNAs (miRNAs) including miRNA-146a, fatty acid-binding protein, urinary metabolomics (tricarboxylic acid and amino acids). This research topic also covers the application of other potential noninvasive biomarkers for diagnosing and monitoring GI disorders. GI cancers are widely regarded as the most harmful and clinically severe conditions affecting the digestive system. In individuals who do not exhibit clinical signs, biomarkers can function as a valuable tool for screening to detect cancer at an early stage or identify precancerous states and, in symptomatic patients, can help distinguish between cancerous and benign conditions. Additionally, with surgical intervention in cancer patients, biomarkers can be useful to assess the efficacy of tumor eradication (remission) and the likelihood of disease relapse. This research topic addresses the latest developments in genetic biomarkers but is not limited to miRNAs and long non-coding RNAs, KRAS mutations, the role of carcinoembryonic antigen, and circulating tumor DNA (ctDNA) as molecular biomarkers for GI malignancies. This topic also explores recent advancements in sepsis biomarkers, including damage-associated molecular patterns (DAMPs), pattern recognition molecules (PRMs), non-coding RNAs, miRNAs, cytokines, cell membrane receptors, metabolites, and soluble receptors. It also discusses the therapeutic challenges posed by antimicrobial resistance and their impact on One Health.
All articles must include genomics or omics data as a central part of their methods. The Research Topic aims to focus on the latest advancements in the field, encompassing both basic research and clinical studies, and invites submissions of Original Research, Reviews, and Methods but is not confined to the following areas:
• Fecal biomarkers for diagnosing and monitoring gastrointestinal disorders
• Identification and characterization of biomarkers for colorectal cancer
• Non-invasive biomarkers for gastrointestinal illnesses
• MicroRNA (miRNA) biomarkers in GI diseases
• Sepsis Biomarkers
• Signaling pathways in sepsis and GI diseases
• Epigenetic biomarkers for GI cancer diagnosis and prognosis
• GI disease epigenetic mechanisms
• Epigenetic biomarkers for GI diseases and sepsis
